Kindred Biosciences, Inc., Opening Near St. Joseph

Kindred Bioscience, Inc., a biopharmaceutical company focused on saving and improving the lives of pets, will open a new 180,000-square-foot facility in Elwood, Kan., near St. Joseph, Mo.

The facility, formerly owned by Boehringer Ingelheim and most recently by Strategic Veterinary Pharmaceuticals, Inc., includes about 8 acres of land and two buildings with clean rooms,  utility, equipment and related quality documentation suitable for small molecule and biologics manufacturing. The company expects to take possession of its new facility in the next 30 days.

Kindred Biosciences selected the location due to its ability to meet the anticipated manufacturing needs of its pipeline, lower its costs of goods and increase its margins. In addition, the company will benefit from the animal health talent in the St. Joseph area.

“We are pleased to welcome Kindred Biosciences to the St. Joseph area to join other animal health companies in the community,” said R. Patt Lilly, President and CEO of the St. Joseph Chamber of Commerce. “The new jobs and investment will be welcomed by our neighbors in Elwood and further solidifies St. Joseph as a major player in the animal health corridor.”

Kindred Biosciences is a California-based development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

No information on the number of jobs to be created are available at this time.